LLY

1,080.21

+1.73%↑

JNJ

223.5

+0.31%↑

ABBV

217.16

+0.73%↑

UNH

377.97

+0.23%↑

MRK

114.86

-0.95%↓

LLY

1,080.21

+1.73%↑

JNJ

223.5

+0.31%↑

ABBV

217.16

+0.73%↑

UNH

377.97

+0.23%↑

MRK

114.86

-0.95%↓

LLY

1,080.21

+1.73%↑

JNJ

223.5

+0.31%↑

ABBV

217.16

+0.73%↑

UNH

377.97

+0.23%↑

MRK

114.86

-0.95%↓

LLY

1,080.21

+1.73%↑

JNJ

223.5

+0.31%↑

ABBV

217.16

+0.73%↑

UNH

377.97

+0.23%↑

MRK

114.86

-0.95%↓

LLY

1,080.21

+1.73%↑

JNJ

223.5

+0.31%↑

ABBV

217.16

+0.73%↑

UNH

377.97

+0.23%↑

MRK

114.86

-0.95%↓

Home・Lista de Ações・Cytokinetics Inc

Cytokinetics Inc

Fechado

SetorSaúde

70.67 -0.07

Comprar Vender

Visão Geral

Variação de preço das ações

24h

Atual

Mín

70.11

Máximo

71.64

Indicadores-chave
By Trading Economics
Rendimento	-23M -206M
Vendas	1.6M 19M
EPS	-1.67
Margem de lucro	-1,064.485
Funcionários	673
EBITDA	112K -180M

Recomendações
By TipRanks
Recomendações	Compra Forte
Previsão para 12 meses	+41.52% upside

Dividendos
By Dow Jones
Próximos Ganhos	6 de ago. de 2026

Estatísticas de Mercado
By TradingEconomics
Capitalização de Mercado	1.8B 10B
Abertura anterior	70.74
Fecho anterior	70.67

Sentimento de Notícias

By Acuity

50%

154 / 344 Ranking em Healthcare

Cytokinetics Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

3 de jun. de 2026, 23:22 UTC

Ganhos

Grandes Movimentos do Mercado

Broadcom Shares Slide Despite Jump in 2Q Revenue on AI Chip Demand -- Update

3 de jun. de 2026, 23:09 UTC

Ações em Alta

Stocks to Watch: Broadcom, CrowdStrike, PVH, Petco

3 de jun. de 2026, 20:51 UTC

Ganhos

Costco Reports 15% Sales Growth in May

3 de jun. de 2026, 20:43 UTC

Ganhos

Broadcom 2Q Revenue Climbs on AI Chip Demand

3 de jun. de 2026, 23:48 UTC

Conversa de Mercado

Nikkei May Fall Amid Renewed Concerns About Iran Conflict -- Market Talk

3 de jun. de 2026, 23:48 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

3 de jun. de 2026, 23:35 UTC

Conversa de Mercado

Oil Futures Fall on Possible Technical Correction -- Market Talk

3 de jun. de 2026, 23:15 UTC

Conversa de Mercado

Ganhos

Five Below, Broadcom and Crowdstrike Fall Despite Solid Results -- Market Talk

3 de jun. de 2026, 22:08 UTC

Ações em Alta

After-Hours Stocks to Watch: CrowdStrike, Broadcom, Five Below -- WSJ

3 de jun. de 2026, 21:54 UTC

Conversa de Mercado

Correction to Oil Futures Rise on Concerns About U.S.-Iran Talks Article on June 1

3 de jun. de 2026, 21:18 UTC

Ganhos

Broadcom's Non-AI Semiconductor Revenue Rose 6% in 2Q, CEO Says

3 de jun. de 2026, 21:15 UTC

Ganhos

Broadcom CEO: Google Partnership Continues to Be 'Very Substantial'

3 de jun. de 2026, 21:13 UTC

Ganhos

Broadcom CEO Expects AI Semiconductor Revenue Growth to Continue in Fiscal 2028

3 de jun. de 2026, 21:13 UTC

Ganhos

Broadcom Continues to Expect AI Semiconductor Revenue of More Than $100B in 2027, CEO Says

3 de jun. de 2026, 21:12 UTC

Ganhos

Broadcom Expects AI Semiconductor Revenue of $56B This Year, CEO Says

3 de jun. de 2026, 21:09 UTC

Ganhos

Broadcom CEO: Networking Made Up Almost 40% of AI Revenue in 2Q

3 de jun. de 2026, 21:03 UTC

Ganhos

Broadcom Stock Falls After Earnings. Here's Why. -- Barrons.com

3 de jun. de 2026, 20:50 UTC

Conversa de Mercado

Tech, Media & Telecom Roundup: Market Talk

3 de jun. de 2026, 20:43 UTC

Ganhos

CrowdStrike Stock Falls Despite Earnings Beat -- Barrons.com

3 de jun. de 2026, 20:39 UTC

Aquisições, Fusões, Aquisições de Empresas

Bill Ackman's Pershing Square Set To Make $600 Million on Universal Stake -- 4th Update

3 de jun. de 2026, 20:37 UTC

Aquisições, Fusões, Aquisições de Empresas

Bill Ackman's Pershing Square Set To Make $600 Million on Universal Stake -- 3rd Update

3 de jun. de 2026, 20:35 UTC

Ganhos

Broadcom Stock Falls Despite Record Results -- Barrons.com

3 de jun. de 2026, 20:21 UTC

Aquisições, Fusões, Aquisições de Empresas

Bill Ackman's Pershing Square Set To Make $600 Million on Universal Stake -- 2nd Update

3 de jun. de 2026, 20:17 UTC

Ganhos

Broadcom 2Q Semiconductor Solutions Revenue $15B >AVGO

3 de jun. de 2026, 20:17 UTC

Ganhos

Broadcom Sees 3Q Semiconductor Revenue From AI $16B >AVGO

3 de jun. de 2026, 20:15 UTC

Aquisições, Fusões, Aquisições de Empresas

Bill Ackman's Pershing Square Set To Make $600 Million on Universal Stake -- Update

3 de jun. de 2026, 20:15 UTC

Ganhos

Broadcom 2Q Adj EPS $2.44 >AVGO

3 de jun. de 2026, 20:15 UTC

Ganhos

Broadcom 2Q EPS $1.91 >AVGO

3 de jun. de 2026, 20:15 UTC

Conversa de Mercado

Global Commodities Roundup: Market Talk

3 de jun. de 2026, 20:15 UTC

Ganhos

Broadcom 2Q Rev $22.19B >AVGO

Comparação entre Pares

Variação de preço

Cytokinetics Inc Previsão

Preço-alvo

By TipRanks

41.52% parte superior

Previsão para 12 meses

Média 100.35 USD 41.52%

Máximo 140 USD

Mínimo 67 USD

Com base em 18 analistas de Wall Street que oferecem metas de preço de 12 meses para Cytokinetics Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

18 ratings

Comprar

Manter

Vender

Com base em 18 analistas que deram avaliações de ações para Cytokinetics Inc - Dist nos últimos 3 meses.

Sentimento

By Acuity

154 / 344 Ranking em Saúde

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

Sobre Cytokinetics Inc

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. It develops small molecule drug candidates primarily engineered to impact muscle function and contractility. The company's drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. It also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. The company has a strategic alliance with Ji Xing Pharmaceuticals Limited; and a collaboration and license agreement for the development and commercialization of aficamten in Japan for the treatment of patients with obstructive and non-obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.